Phase I/II Combination With Irinotecan- Erbitux

A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer

Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC)

Part 2: To compare median duration of progression free survival (PFS)

Inclusion Criteria:

• Biopsy proven MCRC
• Prior irinotecan allowed
• Prior Erbitux allowed

Exclusion Criteria:

• No prior brivanib
• No prior combination of irinotecan with Erbitux
• No secondary malignancies
• No anti-coagulation therapy
• No prior history of blood clots requiring anti-coagulation